Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Outlook Therapeutics (OTLK) EBITDA Margin (2016 - 2025)

Outlook Therapeutics (OTLK) has disclosed EBITDA Margin for 7 consecutive years, with 18863.9% as the latest value for Q3 2025.

  • Quarterly EBITDA Margin changed N/A to 18863.9% in Q3 2025 from the year-ago period, while the trailing twelve-month figure was 4169.6% through Dec 2025, down 695725.0% year-over-year, with the annual reading at 4744.25% for FY2025, 701552.0% down from the prior year.
  • EBITDA Margin for Q3 2025 was 18863.9% at Outlook Therapeutics, up from 1046.2% in the prior quarter.
  • The five-year high for EBITDA Margin was 18863.9% in Q3 2025, with the low at 1046.2% in Q2 2025.